DIVISLAB9,415.00

Divi's Laboratories Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersLAURUSLABSCOHANCEGLANDTORNTPHARMZYDUSLIFEMAXHEALTHDRREDDYCIPLAMcap ₹2.49L Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations7,845.09,360.010,560.011,230.0
Other Income339.0352.0507.0452.0
Total Income8,184.09,712.011,067.011,682.0
Expenses
+ Cost of Materials Consumed3,232.03,821.04,378.04,871.0
+ Purchases of Stock-in-Trade6.00.00.00.0
+ Changes in Inventories-109.0-96.0-285.0-748.0
+ Employee Benefit Expense1,094.01,243.01,442.01,510.0
+ Finance Costs3.02.023.026.0
+ Depreciation & Amortisation378.0402.0463.0484.0
+ Other Expenses1,417.01,424.01,584.01,630.0
Total Expenses6,021.06,796.07,605.07,773.0
EBITDA2,205.02,968.03,441.03,967.0
EBIT1,827.02,566.02,978.03,483.0
Profit
PBT before Exceptional Items2,163.02,916.03,462.03,909.0
+ Exceptional Items0.00.0-74.0-74.0
Pretax Income2,163.02,916.03,388.03,835.0
+ Current Tax514.0799.0868.0968.0
+ Deferred Tax49.0-74.0-48.0-58.0
Tax Expense563.0725.0820.0910.0
Net Income1,600.02,191.02,568.02,925.0
+ Net Income — Continuing Ops1,600.02,191.02,568.02,925.0
+ Other Comprehensive Income0.03.021.020.0
Total Comprehensive Income1,600.02,194.02,589.02,945.0
Net Income to Common1,600.02,191.02,568.02,925.0
Per Share
Basic EPS60.2782.5396.75110.21
Diluted EPS60.2782.5396.75110.21
Other Comprehensive Income — detail
+ Other Comprehensive Income3.021.020.0
+ Items NOT to be Reclassified to P&L-2.0-3.08.011.0
+ Tax on Items NOT to be Reclassified1.02.03.0
+ Tax on Items NOT to be Reclassified — alt tag-1.0
+ Items to be Reclassified to P&L2.06.020.017.0
+ Tax on Items to be Reclassified-1.05.05.0
+ Tax on Items to be Reclassified — alt tag1.0
Comprehensive Income — Owners of Parent1,600.02,194.02,589.02,945.0
Per Share — as-filed variants
Basic EPS — Continuing Operations60.2782.5396.75110.21
Diluted EPS — Continuing Operations60.2782.5396.75110.21
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit4,716.05,635.06,467.07,107.0
Gross Margin %60.1160.2061.2463.29
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)2,163.02,916.03,462.03,909.0
− Exceptional Items (reconciliation)0.00.0-74.0-74.0
Net Income Adj (tax-effected)1,600.02,191.02,624.12,981.4
EPS Adj60.2782.5398.86112.34
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital53.053.053.053.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.